Loading patent…
AssigneesPeg-Bio Biopharm Co.,Ltd.(Chongqing), Hangzhou Grand Biologic Pharmaceutical Inc.
InventorsKai FAN, Zhiming WANG, Riyong LIU, Yu WANG, Yunfeng HE, Tianwen YAN, Zhicheng FU, Guowei SU, Chunlan HU, Xupeng DING, Changcheng TAN, Hongying WANG, Hui YANG, Qiong DING, Haiyan WEN
Estimating the term…
The present disclosure provides a polyethylene glycol-modified urate oxidase. At least 11 of the following amino acid sites in the urate oxidase have a PEG modification: T1, K3, K4, K30, K35, K76, K79, K97, K112, K116, K120, K152, K179, K222, K231, K266, K272, K285, K291, and K293.
A polyethylene glycol-modified urate oxidase, wherein at least 11 of the following amino acid sites in the urate oxidase have a PEG modification:
A polyethylene glycol-modified urate oxidase, wherein peak areas of at least 11 predetermined peptide fragments in a peptide map of the polyethylene glycol-modified urate oxidase are reduced by a relative proportion of 75% or more, preferably 80% or more, more preferably 90% or more, compared with those in a peptide map of urate oxidase unmodified with polyethylene glycol.
A method for reducing immunogenicity of urate oxidase, comprising:
Dependencies are inferred from the claim text.